**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Diagnostics Assessment Programme**

**EarlyCDT Lung for lung cancer risk classification of solid pulmonary nodules**

**Final stakeholder list**

**Manufacturer**

Oncimmune Ltd

**Professional groups**

British Thoracic Society

Royal College of Physicians

The Royal College of Pathologists

**Patient/carer groups**

Roy Castle Lung Cancer Foundation

**External Assessment Group**

Centre for Reviews and Dissemination and Centre for Health Economics, University of York

**Others**

Association of British HealthTech Industries (ABHI)

Department of Health

Healthcare Improvement Scotland

Medicines and Healthcare products Regulatory Agency

NHS England

Welsh Government

**Definitions:**

Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology.